Advaxis Stock Analysis (NASDAQ:ADXS)

Add to My Stocks
$8.46 $0.11 (1.28%) ADXS stock closing price Feb 24, 2017 (Closing)
Watch Robo Advisor Video of ADXS Stock Analysis
Advaxis
Updated on : Feb 24, 2017
previous close
ADXS 8.5 (0%)
S&P 500 2367.3 (0%)
Closing Price On: Feb 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-1917%
Sector Average:
-1.1%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Debt/Equity Ratio
Debt:
0.4M
Debt/Equity Ratio:
 0
Compared to the industry
Cash Flow
Operating cash flow:
$22.1M
Net Income:
-$21.7M
PROS      CONS
Low Debt Burden
FCF Margin
Recent Growth
Operating Margins
Net Margins
ROE
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Equity:
-70.9%
Free Cash Flow Margin:
557.5%
Double Tap To Exit Full Screen
0:00
/

Advaxis Analysis Video

130 5 2

View Advaxis stock analysis video. This is our ADXS analyst opinion covering the buy and sell arguments for ADXS stock.

Advaxis, Inc. Stock Rating (1.5/5)

Our Advaxis stock opinion is based on fundamentals of the company. This Advaxis stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ADXS stock?

  • With a debt/equity ratio of  0, Advaxis is comparatively less leveraged than its peers in the Medical sector.
  • Advaxis has a healthy FCF (Free Cash Flow) margin of 557.5%.

Should you sell ADXS stock?

  • Advaxis revenue saw a decline of -999% YoY in 2016 Q4.
  • Advaxis reported an average operating margin of -1917% over the Last Twelve Months (LTM).
  • Advaxis posted an average Net loss of -1843.9% in the last twelve months.
  • A negative ROE of -70.9% indicates that the company is not able to generate profits with the money shareholders have invested.

Comments on this video and Advaxis stock